What happens when the vial inspection method you’ve relied on for years suddenly starts missing defects? That’s exactly the challenge one contract manufacturing organization (CMO) faced when its semi-automated visual inspection process began failing. What followed was a journey that would fundamentally change how they approached quality control in pharmaceutical manufacturing.
This case study considers the wider challenges of difficult-to-inspect vials, how automatic inspection systems work, and why AI-based approaches succeed where standard methods fail
Types of Vial Inspection Equipment
There are three primary approaches to vial inspection, each yielding different trade-offs among speed, accuracy, and cost.
Manual vial inspection relies entirely on trained human inspectors who examine each unit against a controlled light source, and while this method remains common throughout the pharmaceutical industry, it suffers from inspector fatigue and throughput limitations that rarely exceed 20 units per minute even under optimal conditions.
Semi-automated vial inspection combines mechanical handling with human decision-making to improve efficiency without fully excluding the human element. These systems transport vials through an inspection station where operators view magnified images under optimized lighting, pushing throughput to 25-35 units per minute.
Automated vial inspection eliminates manual evaluation entirely. Fully automated systems use machine vision and artificial intelligence to analyze hundreds of images per unit at high speed, frequently exceeding 50 units per minute, while the vial inspection machine handles everything from infeed to ejection without operator intervention for individual accept/reject decisions.
How Traditional Automated Visual Inspection (AVI) Systems Work
Automated visual inspection uses high-definition cameras, controlled lighting, and intelligent software to evaluate pharmaceutical products as they move through the production line. As items such as vials, tablets, or syringes pass inspection points, cameras capture high-resolution images that are analyzed in real time by algorithms trained to detect defects using supervised machine learning and traditional computer vision techniques such as image subtraction and pattern recognition.
Challenge with Traditional Automatic Vial Inspection Machines
Most automated visual inspection systems face difficulties in pharmaceutical manufacturing because they are built on assumptions that don’t match reality. Traditional rule-based machine vision systems are brittle when faced with products that show considerable normal variation, such as molded glass, powders, lyophilized products, and prefilled syringes. As quality expectations rise, these systems either miss subtle defects or overcorrect, driving false reject rates into the double digits and forcing manufacturers back to manual inspection.
The industry’s push toward supervised AI has not solved this problem. Defect classifiers rely on large, labeled datasets of known defects, which are costly and difficult to assemble. Even when data is available, it is often incomplete because defects are, by nature, rare and unpredictable events.
Failed AQLs as a Result of Poor Vial Inspection
The product at the center of this case study was a 20-mL powder-filled molded glass vial, and it presented exactly the kind of nightmare scenario that exposes the limitations of typical vial inspection equipment. The powder refused to settle uniformly from one unit to the next, creating endless visual variation that made consistent inspection nearly impossible, while the natural variability intrinsic in molded glass containers additionally compounded the problem.
The CMO’s semi-automated inspection process began missing defects at an alarming rate. Each AQL failure triggered production delays. Defects were getting through to final release, creating compliance concerns and threatening relationships with the manufacturing sponsor, who expected reliable product quality as a non-negotiable.
Traditional automatic vial inspection machine systems were considered but quickly ruled out. These established approaches have historically struggled with exactly this type of complexity—products where normal variation looks almost indistinguishable from actual defects, where the inspection process must somehow learn to tolerate acceptable randomness while still catching genuine problems. The CMO began evaluating whether AI-based inspection could finally deliver the flexibility and consistency the product required.
Why Our Vial Inspection Machine Was Able to Outperform Human Inspectors
Following a preliminary feasibility study that confirmed the product was well-suited for AI-based automatic visual inspection, the CMO selected the DAI-50, powered by AVIS, for an on-site performance evaluation in partnership with Boon Logic.
Within hours of starting the test, the inspection environment was fully optimized. Lighting, camera angles, and regions of interest were configured to reflect real production conditions. Using just 500 pre-inspected, compliant units, the team created a validation-ready inspection recipe which captured the full spectrum of acceptable variation in the powder-filled vials. This included natural powder movement, adhesion to the vial sidewalls, and acceptable fill-level variability—conditions that routinely overwhelm traditional rule-based systems and drive excessive false rejects.
Once trained, the DAI-50 began inspecting vials it had never seen before.
Detection Capabilities of Our Vial Inspection Machine, the DAI-50
To validate performance, the CMO supplied a customer-defined defect set along with a holdback set of compliant vials that had been completely excluded from training. The inspection results were decisive.
The DAI-50 demonstrated performance equal to or better than human inspectors, achieving 98% overall defect-detection accuracy spanning the full range of defect types while continuing a false reject rate of just 2.7%. Both the CMO and the manufacturing sponsor were pleased with the study’s outcomes. The CMO subsequently leveraged the results to secure funding for the DAI-50 system, citing the measurable improvement in product quality and inspection consistency as a clear business and quality justification. Though an exact ROI for this case study was not provided by the client, other use cases using the DAI-50 as a syringe inspection machine have demonstrated an ROI exceeding $3 million in annual value.
Process for System Validation and Qualification
The DAI-50 follows established IQ, OQ, and PQ validation workflows to demonstrate the system meets or exceeds human inspector capabilities.
Installation Qualification confirms all hardware and software components are correctly installed. Operational Qualification verifies system functionality via comprehensive testing, including the recipe development workflow, during which AVIS trains on 300-500 compliant units. A Knapp study shows that inspection performance is equal to or exceeds that of human inspectors.
Performance Qualification validates uniform performance under real production conditions through three consecutive live batches with elevated AQL sampling.
Because AVIS learns directly from compliant products rather than entailing extensive defect libraries, manufacturers reach GMP readiness faster. The result is a predictable path to validated automated solutions that protect patient safety while increasing throughput.
